{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T02:53:51Z","timestamp":1793933631503,"version":"4.8.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:00:00Z","timestamp":1761004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:00:00Z","timestamp":1761004800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100004731","name":"Natural Science Foundation of Zhejiang Province","doi-asserted-by":"publisher","award":["LMS25B050002"],"award-info":[{"award-number":["LMS25B050002"]}],"id":[{"id":"10.13039\/501100004731","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Noncommunicable Chronic Diseases-National Science and Technology Major Project","award":["2023ZD0501600"],"award-info":[{"award-number":["2023ZD0501600"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["52233013"],"award-info":[{"award-number":["52233013"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"the \"Pioneer\" and \"Leading Goose\" R&D Program of Zhejiang Province","award":["2023C03061"],"award-info":[{"award-number":["2023C03061"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"DOI":"10.1007\/s00262-025-04196-9","type":"journal-article","created":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T06:42:17Z","timestamp":1761028937000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["NKG2D CAR-NK adoptive cellular immunotherapy combined with or without PD-1 blockade in the treatment of patients with metastatic colorectal cancer: an exploratory study"],"prefix":"10.1007","volume":"74","author":[{"given":"Danyang","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guojie","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hangyu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhicheng","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaomeng","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuanwen","family":"Bao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xudong","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhou","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongxue","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lulu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weijia","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,21]]},"reference":[{"key":"4196_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I et al (2024) Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 74:229\u2013263. https:\/\/doi.org\/10.3322\/caac.21834","journal-title":"CA Cancer J Clin"},{"key":"4196_CR2","doi-asserted-by":"publisher","first-page":"308","DOI":"10.3322\/caac.70011","volume":"75","author":"NS Wagle","year":"2025","unstructured":"Wagle NS, Nogueira L, Devasia TP, Mariotto AB, Yabroff KR, Islami F et al (2025) Cancer treatment and survivorship statistics, 2025. CA Cancer J Clin 75:308\u2013340. https:\/\/doi.org\/10.3322\/caac.70011","journal-title":"CA Cancer J Clin"},{"key":"4196_CR3","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1038\/s41575-019-0126-x","volume":"16","author":"K Ganesh","year":"2019","unstructured":"Ganesh K, Stadler ZK, Cercek A, Mendelsohn RB, Shia J, Segal NH et al (2019) Immunotherapy in colorectal cancer: rationale, challenges and potential. Nat Rev Gastroenterol Hepatol 16:361\u2013375. https:\/\/doi.org\/10.1038\/s41575-019-0126-x","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"4196_CR4","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1001\/jama.2021.0106","volume":"325","author":"LH Biller","year":"2021","unstructured":"Biller LH, Schrag D (2021) Diagnosis and treatment of metastatic colorectal cancer: a review. JAMA 325:669\u2013685. https:\/\/doi.org\/10.1001\/jama.2021.0106","journal-title":"JAMA"},{"key":"4196_CR5","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1038\/s41571-021-00495-z","volume":"18","author":"F Di Nicolantonio","year":"2021","unstructured":"Di Nicolantonio F, Vitiello PP, Marsoni S, Siena S, Tabernero J, Trusolino L et al (2021) Precision oncology in metastatic colorectal cancer-from biology to medicine. Nat Rev Clin Oncol 18:506\u2013525","journal-title":"Nat Rev Clin Oncol"},{"key":"4196_CR6","doi-asserted-by":"publisher","first-page":"3834","DOI":"10.3748\/wjg.v24.i34.3834","volume":"24","author":"K Van der Jeught","year":"2018","unstructured":"Van der Jeught K, Xu HC, Li YJ, Lu XB, Ji G (2018) Drug resistance and new therapies in colorectal cancer. World J Gastroenterol 24:3834\u20133848. https:\/\/doi.org\/10.3748\/wjg.v24.i34.3834","journal-title":"World J Gastroenterol"},{"key":"4196_CR7","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1016\/s1470-2045(17)30422-9","volume":"18","author":"MJ Overman","year":"2017","unstructured":"Overman MJ, McDermott R, Leach JL, Lonardi S, Lenz HJ, Morse MA et al (2017) Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol 18:1182\u20131191. https:\/\/doi.org\/10.1016\/s1470-2045(17)30422-9","journal-title":"Lancet Oncol"},{"key":"4196_CR8","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/s0140-6736(24)02848-4","volume":"405","author":"T Andr\u00e9","year":"2025","unstructured":"Andr\u00e9 T, Elez E, Lenz HJ, Jensen LH, Touchefeu Y, Van Cutsem E et al (2025) Nivolumab plus ipilimumab versus nivolumab in microsatellite instability-high metastatic colorectal cancer (CheckMate 8HW): a randomised, open-label, phase 3 trial. Lancet 405:383\u2013395. https:\/\/doi.org\/10.1016\/s0140-6736(24)02848-4","journal-title":"Lancet"},{"key":"4196_CR9","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1038\/s41577-022-00732-1","volume":"23","author":"NK Wolf","year":"2023","unstructured":"Wolf NK, Kissiov DU, Raulet DH (2023) Roles of natural killer cells in immunity to cancer, and applications to immunotherapy. Nat Rev Immunol 23:90\u2013105. https:\/\/doi.org\/10.1038\/s41577-022-00732-1","journal-title":"Nat Rev Immunol"},{"key":"4196_CR10","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.smim.2014.02.007","volume":"26","author":"N Shifrin","year":"2014","unstructured":"Shifrin N, Raulet DH, Ardolino M (2014) NK cell self tolerance, responsiveness and missing self recognition. Semin Immunol 26:138\u2013144. https:\/\/doi.org\/10.1016\/j.smim.2014.02.007","journal-title":"Semin Immunol"},{"key":"4196_CR11","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005308","author":"SY Neo","year":"2022","unstructured":"Neo SY, Jing X, Tong L, Tong D, Gao J, Chen Z et al (2022) Tumor MHC class I expression alters cancer-associated myelopoiesis driven by host NK cells. J Immunother Cancer. https:\/\/doi.org\/10.1136\/jitc-2022-005308","journal-title":"J Immunother Cancer"},{"key":"4196_CR12","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.coi.2018.03.013","volume":"51","author":"M Daher","year":"2018","unstructured":"Daher M, Rezvani K (2018) Next generation natural killer cells for cancer immunotherapy: the promise of genetic engineering. Curr Opin Immunol 51:146\u2013153. https:\/\/doi.org\/10.1016\/j.coi.2018.03.013","journal-title":"Curr Opin Immunol"},{"key":"4196_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12071760","author":"AM Cornel","year":"2020","unstructured":"Cornel AM, Mimpen IL, Nierkens S (2020) MHC class I downregulation in cancer: underlying mechanisms and potential targets for cancer immunotherapy. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers12071760","journal-title":"Cancers (Basel)"},{"key":"4196_CR14","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1038\/s41423-024-01207-0","volume":"21","author":"L Peng","year":"2024","unstructured":"Peng L, Sferruzza G, Yang L, Zhou L, Chen S (2024) CAR-T and CAR-NK as cellular cancer immunotherapy for solid tumors. Cell Mol Immunol 21:1089\u20131108","journal-title":"Cell Mol Immunol"},{"key":"4196_CR15","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1038\/s43018-025-00940-3","volume":"6","author":"W Lei","year":"2025","unstructured":"Lei W, Liu H, Deng W, Chen W, Liang Y, Gao W et al (2025) Safety and feasibility of 4\u20131BB co-stimulated CD19-specific CAR-NK cell therapy in refractory\/relapsed large B cell lymphoma: a phase 1 trial. Nat Cancer 6:786\u2013800. https:\/\/doi.org\/10.1038\/s43018-025-00940-3","journal-title":"Nat Cancer"},{"key":"4196_CR16","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1038\/s41591-023-02785-8","volume":"30","author":"D Marin","year":"2024","unstructured":"Marin D, Li Y, Basar R, Rafei H, Daher M, Dou J et al (2024) Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19(+) B cell tumors: a phase 1\/2 trial. Nat Med 30:772\u2013784. https:\/\/doi.org\/10.1038\/s41591-023-02785-8","journal-title":"Nat Med"},{"key":"4196_CR17","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1056\/NEJMoa1910607","volume":"382","author":"E Liu","year":"2020","unstructured":"Liu E, Marin D, Banerjee P, Macapinlac HA, Thompson P, Basar R et al (2020) Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors. N Engl J Med 382:545\u2013553. https:\/\/doi.org\/10.1056\/NEJMoa1910607","journal-title":"N Engl J Med"},{"key":"4196_CR18","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/s0140-6736(24)02462-0","volume":"405","author":"A Ghobadi","year":"2025","unstructured":"Ghobadi A, Bachanova V, Patel K, Park JH, Flinn I, Riedell PA et al (2025) Induced pluripotent stem-cell-derived CD19-directed chimeric antigen receptor natural killer cells in B-cell lymphoma: a phase 1, first-in-human trial. Lancet 405:127\u2013136. https:\/\/doi.org\/10.1016\/s0140-6736(24)02462-0","journal-title":"Lancet"},{"key":"4196_CR19","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1186\/s12967-024-05851-y","volume":"22","author":"E Torchiaro","year":"2024","unstructured":"Torchiaro E, Cortese M, Petti C, Basirico M, Invrea F, D\u2019Andrea A et al (2024) Repurposing anti-mesothelin CAR-NK immunotherapy against colorectal cancer. J Transl Med 22:1100. https:\/\/doi.org\/10.1186\/s12967-024-05851-y","journal-title":"J Transl Med"},{"key":"4196_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-024-02418-6","author":"S Yang","year":"2024","unstructured":"Yang S, Sheffer M, Kaplan IE, Wang Z, Tarannum M, Dinh K et al (2024) Non-pathogenic E. coli displaying decoy-resistant IL18 mutein boosts anti-tumor and CAR NK cell responses. Nat Biotechnol. https:\/\/doi.org\/10.1038\/s41587-024-02418-6","journal-title":"Nat Biotechnol"},{"key":"4196_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-025-02158-2","volume":"10","author":"J Luo","year":"2025","unstructured":"Luo J, Guo M, Huang M, Liu Y, Qian Y, Liu Q et al (2025) Neoleukin-2\/15-armored CAR-NK cells sustain superior therapeutic efficacy in solid tumors via c-Myc\/NRF1 activation. Signal Transduct Target Ther 10:78. https:\/\/doi.org\/10.1038\/s41392-025-02158-2","journal-title":"Signal Transduct Target Ther"},{"key":"4196_CR22","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1016\/j.ymthe.2019.03.011","volume":"27","author":"L Xiao","year":"2019","unstructured":"Xiao L, Cen D, Gan H, Sun Y, Huang N, Xiong H et al (2019) Adoptive transfer of NKG2D CAR mRNA-engineered natural killer cells in colorectal cancer patients. Mol Ther 27:1114\u20131125. https:\/\/doi.org\/10.1016\/j.ymthe.2019.03.011","journal-title":"Mol Ther"},{"key":"4196_CR23","doi-asserted-by":"publisher","first-page":"2208697","DOI":"10.1080\/19420862.2023.2208697","volume":"15","author":"KA Whalen","year":"2023","unstructured":"Whalen KA, Rakhra K, Mehta NK, Steinle A, Michaelson JS, Baeuerle PA (2023) Engaging natural killer cells for cancer therapy via NKG2D, CD16A and other receptors. MAbs 15:2208697. https:\/\/doi.org\/10.1080\/19420862.2023.2208697","journal-title":"MAbs"},{"key":"4196_CR24","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00476","volume":"9","author":"A Zingoni","year":"2018","unstructured":"Zingoni A, Molfetta R, Fionda C, Soriani A, Paolini R, Cippitelli M et al (2018) NKG2D and Its Ligands: \u201cOne for All, All for One.\u201d Front Immunol 9:476. https:\/\/doi.org\/10.3389\/fimmu.2018.00476","journal-title":"Front Immunol"},{"key":"4196_CR25","doi-asserted-by":"publisher","DOI":"10.3390\/biology12081079","author":"G Tan","year":"2023","unstructured":"Tan G, Spillane KM, Maher J (2023) The role and regulation of the NKG2D\/NKG2D ligand system in cancer. Biology. https:\/\/doi.org\/10.3390\/biology12081079","journal-title":"Biology"},{"key":"4196_CR26","doi-asserted-by":"publisher","first-page":"6993","DOI":"10.1158\/1078-0432.Ccr-09-0991","volume":"15","author":"RW McGilvray","year":"2009","unstructured":"McGilvray RW, Eagle RA, Watson NF, Al-Attar A, Ball G, Jafferji I et al (2009) NKG2D ligand expression in human colorectal cancer reveals associations with prognosis and evidence for immunoediting. Clin Cancer Res 15:6993\u20137002. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-09-0991","journal-title":"Clin Cancer Res"},{"key":"4196_CR27","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1182\/blood-2014-02-556837","volume":"124","author":"M Imamura","year":"2014","unstructured":"Imamura M, Shook D, Kamiya T, Shimasaki N, Chai SM, Coustan-Smith E et al (2014) Autonomous growth and increased cytotoxicity of natural killer cells expressing membrane-bound interleukin-15. Blood 124:1081\u20131088. https:\/\/doi.org\/10.1182\/blood-2014-02-556837","journal-title":"Blood"},{"key":"4196_CR28","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1038\/leu.2017.226","volume":"32","author":"E Liu","year":"2018","unstructured":"Liu E, Tong Y, Dotti G, Shaim H, Savoldo B, Mukherjee M et al (2018) Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity. Leukemia 32:520\u2013531. https:\/\/doi.org\/10.1038\/leu.2017.226","journal-title":"Leukemia"},{"key":"4196_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2025.05.026","author":"B Li","year":"2025","unstructured":"Li B, Zhu X, Ge J, Zhang H, Gao Y, Bao X et al (2025) Intraperitoneal infusion of NKG2D CAR-NK cells induces endogenous CD8(+) T cell activation in patients with advanced colorectal cancer. Mol Ther. https:\/\/doi.org\/10.1016\/j.ymthe.2025.05.026","journal-title":"Mol Ther"},{"key":"4196_CR30","doi-asserted-by":"publisher","first-page":"98","DOI":"10.3109\/14653249.2010.515582","volume":"13","author":"MA Geller","year":"2011","unstructured":"Geller MA, Cooley S, Judson PL, Ghebre R, Carson LF, Argenta PA et al (2011) A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer. Cytotherapy 13:98\u2013107. https:\/\/doi.org\/10.3109\/14653249.2010.515582","journal-title":"Cytotherapy"},{"key":"4196_CR31","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1016\/j.jcyt.2013.05.022","volume":"15","author":"MA Geller","year":"2013","unstructured":"Geller MA, Knorr DA, Hermanson DA, Pribyl L, Bendzick L, McCullar V et al (2013) Intraperitoneal delivery of human natural killer cells for treatment of ovarian cancer in a mouse xenograft model. Cytotherapy 15:1297\u20131306. https:\/\/doi.org\/10.1016\/j.jcyt.2013.05.022","journal-title":"Cytotherapy"},{"key":"4196_CR32","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/j.omtm.2021.10.014","volume":"23","author":"Z Du","year":"2021","unstructured":"Du Z, Ng YY, Zha S, Wang S (2021) Piggybac system to co-express NKG2D CAR and IL-15 to augment the in vivo persistence and anti-AML activity of human peripheral blood NK cells. Mol Ther 23:582\u2013596. https:\/\/doi.org\/10.1016\/j.omtm.2021.10.014","journal-title":"Mol Ther"},{"key":"4196_CR33","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1038\/s41591-022-01726-1","volume":"28","author":"V Narayan","year":"2022","unstructured":"Narayan V, Barber-Rotenberg JS, Jung IY, Lacey SF, Rech AJ, Davis MM et al (2022) PSMA-targeting TGF\u03b2-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial. Nat Med 28:724\u2013734. https:\/\/doi.org\/10.1038\/s41591-022-01726-1","journal-title":"Nat Med"},{"key":"4196_CR34","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/mt.2010.24","volume":"18","author":"RA Morgan","year":"2010","unstructured":"Morgan RA, Yang JC, Kitano M, Dudley ME, Laurencot CM, Rosenberg SA (2010) Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther 18:843\u2013851. https:\/\/doi.org\/10.1038\/mt.2010.24","journal-title":"Mol Ther"},{"key":"4196_CR35","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/s41591-018-0041-7","volume":"24","author":"T Giavridis","year":"2018","unstructured":"Giavridis T, van der Stegen SJC, Eyquem J, Hamieh M, Piersigilli A, Sadelain M (2018) CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade. Nat Med 24:731\u2013738. https:\/\/doi.org\/10.1038\/s41591-018-0041-7","journal-title":"Nat Med"},{"key":"4196_CR36","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1080\/14712598.2020.1729735","volume":"20","author":"CK Chou","year":"2020","unstructured":"Chou CK, Turtle CJ (2020) Assessment and management of cytokine release syndrome and neurotoxicity following CD19 CAR-T cell therapy. Expert Opin Biol Ther 20:653\u2013664. https:\/\/doi.org\/10.1080\/14712598.2020.1729735","journal-title":"Expert Opin Biol Ther"},{"key":"4196_CR37","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0739-1","volume":"7","author":"B Mart\u00edn-Antonio","year":"2019","unstructured":"Mart\u00edn-Antonio B, Su\u00f1e G, Najjar A, Perez-Amill L, Anto\u00f1ana-Vildosola A, Castella M et al (2019) Extracellular NK histones promote immune cell anti-tumor activity by inducing cell clusters through binding to CD138 receptor. J Immunother Cancer 7:259. https:\/\/doi.org\/10.1186\/s40425-019-0739-1","journal-title":"J Immunother Cancer"},{"key":"4196_CR38","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1038\/s41590-020-0728-z","volume":"21","author":"T Bald","year":"2020","unstructured":"Bald T, Krummel MF, Smyth MJ, Barry KC (2020) The NK cell-cancer cycle: advances and new challenges in NK cell-based immunotherapies. Nat Immunol 21:835\u2013847. https:\/\/doi.org\/10.1038\/s41590-020-0728-z","journal-title":"Nat Immunol"},{"key":"4196_CR39","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaz5618","author":"F Cichocki","year":"2020","unstructured":"Cichocki F, Bjordahl R, Gaidarova S, Mahmood S, Abujarour R, Wang H et al (2020) Ipsc-derived NK cells maintain high cytotoxicity and enhance in vivo tumor control in concert with T cells and anti\u2013PD-1 therapy. Sci Transl Med. https:\/\/doi.org\/10.1126\/scitranslmed.aaz5618","journal-title":"Sci Transl Med"},{"key":"4196_CR40","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-006596","author":"DP Turicek","year":"2023","unstructured":"Turicek DP, Giordani VM, Moraly J, Taylor N, Shah NN (2023) CAR t-cell detection scoping review: an essential biomarker in critical need of standardization. J Immunother Cancer. https:\/\/doi.org\/10.1136\/jitc-2022-006596","journal-title":"J Immunother Cancer"},{"key":"4196_CR41","doi-asserted-by":"publisher","first-page":"2789","DOI":"10.1016\/j.ymthe.2025.01.036","volume":"33","author":"B Tan","year":"2025","unstructured":"Tan B, Tu C, Xiong H, Xu Y, Shi X, Zhang X et al (2025) GITRL enhances cytotoxicity and persistence of CAR-T cells in cancer therapy. Mol Ther 33:2789\u20132800. https:\/\/doi.org\/10.1016\/j.ymthe.2025.01.036","journal-title":"Mol Ther"},{"key":"4196_CR42","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/s41568-022-00491-0","volume":"22","author":"TJ Laskowski","year":"2022","unstructured":"Laskowski TJ, Biederst\u00e4dt A, Rezvani K (2022) Natural killer cells in antitumour adoptive cell immunotherapy. Nat Rev Cancer 22:557\u2013575. https:\/\/doi.org\/10.1038\/s41568-022-00491-0","journal-title":"Nat Rev Cancer"},{"key":"4196_CR43","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1158\/2159-8290.Cd-20-0655","volume":"11","author":"B C\u00f3zar","year":"2021","unstructured":"C\u00f3zar B, Greppi M, Carpentier S, Narni-Mancinelli E, Chiossone L, Vivier E (2021) Tumor-infiltrating natural killer cells. Cancer Discov 11:34\u201344. https:\/\/doi.org\/10.1158\/2159-8290.Cd-20-0655","journal-title":"Cancer Discov"},{"key":"4196_CR44","doi-asserted-by":"publisher","DOI":"10.1038\/s41420-024-01815-9","volume":"10","author":"W Wang","year":"2024","unstructured":"Wang W, Liu Y, He Z, Li L, Liu S, Jiang M et al (2024) Breakthrough of solid tumor treatment: CAR-NK immunotherapy. Cell Death Discov 10:40. https:\/\/doi.org\/10.1038\/s41420-024-01815-9","journal-title":"Cell Death Discov"},{"key":"4196_CR45","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-025-02386-8","volume":"24","author":"SS Azeez","year":"2025","unstructured":"Azeez SS, Yashooa RK, Smail SW, Salihi A, Ali AS, Mamand S et al (2025) Advancing CAR-based cell therapies for solid tumours: challenges, therapeutic strategies, and perspectives. Mol Cancer 24:191. https:\/\/doi.org\/10.1186\/s12943-025-02386-8","journal-title":"Mol Cancer"},{"key":"4196_CR46","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1038\/ni.3470","volume":"17","author":"RB Delconte","year":"2016","unstructured":"Delconte RB, Kolesnik TB, Dagley LF, Rautela J, Shi W, Putz EM et al (2016) CIS is a potent checkpoint in NK cell-mediated tumor immunity. Nat Immunol 17:816\u2013824. https:\/\/doi.org\/10.1038\/ni.3470","journal-title":"Nat Immunol"},{"key":"4196_CR47","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-021-01083-5","volume":"14","author":"Y Gong","year":"2021","unstructured":"Gong Y, Klein Wolterink RGJ, Wang J, Bos GMJ, Germeraad WTV (2021) Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy. J Hematol Oncol 14:73. https:\/\/doi.org\/10.1186\/s13045-021-01083-5","journal-title":"J Hematol Oncol"},{"key":"4196_CR48","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1158\/2326-6066.Cir-21-1052","volume":"10","author":"F Souza-Fonseca-Guimaraes","year":"2022","unstructured":"Souza-Fonseca-Guimaraes F, Rossi GR, Dagley LF, Foroutan M, McCulloch TR, Yousef J et al (2022) TGF\u03b2 and CIS inhibition overcomes NK-cell suppression to restore antitumor immunity. Cancer Immunol Res 10:1047\u20131054. https:\/\/doi.org\/10.1158\/2326-6066.Cir-21-1052","journal-title":"Cancer Immunol Res"},{"key":"4196_CR49","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/j.jcyt.2016.12.005","volume":"19","author":"ES Yvon","year":"2017","unstructured":"Yvon ES, Burga R, Powell A, Cruz CR, Fernandes R, Barese C et al (2017) Cord blood natural killer cells expressing a dominant negative TGF-\u03b2 receptor: implications for adoptive immunotherapy for glioblastoma. Cytotherapy 19:408\u2013418. https:\/\/doi.org\/10.1016\/j.jcyt.2016.12.005","journal-title":"Cytotherapy"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-025-04196-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-025-04196-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-025-04196-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T17:20:07Z","timestamp":1763054407000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-025-04196-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,21]]},"references-count":49,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,11]]}},"alternative-id":["4196"],"URL":"https:\/\/doi.org\/10.1007\/s00262-025-04196-9","relation":{},"ISSN":["1432-0851"],"issn-type":[{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,21]]},"assertion":[{"value":"13 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"S.W. holds employment and equity interest in Hangzhou CNK Therapeutics Co., Ltd. All other authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the Ethics Committee of the First Affiliated Hospital, School of Medicine, Zhejiang University, and conducted in accordance with the principles of the Declaration of Helsinki. Written informed consent was obtained from all participants.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}}],"article-number":"341"}}